Want to see JP:4912 full AI Analyst Report?
Top Page
Lion
(4912)
Select Model
Select Model
Rating:75Outperform
Price Target:
¥2,022.00
▲(21.84% Upside)
Action:Upgraded
Date:08/10/26
The score is driven primarily by improving profitability and a conservative, strengthening balance sheet, supported by strong price trend vs. moving averages and positive momentum. This is tempered by only modest revenue growth, a history of cash-flow volatility, and valuation that looks fair rather than clearly discounted (P/E 17.724 with a ~1.61% dividend yield).
Positive Factors
Margin Recovery
The material margin recovery since 2023 reflects sustained cost control and/or product-mix improvements that are translating into higher operating and net profitability. Improved margins enhance durable earnings power and buffer against input-cost shocks, supporting long-term cash generation and reinvestment capacity.
Negative Factors
Modest Revenue Growth
Sub-3% top-line growth reflects category constraints and limits structural earnings upside absent continued margin gains. Slow organic revenue expansion makes profits more reliant on cost improvements or pricing, increasing sensitivity to competitive or input-cost pressures over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Recovery
The material margin recovery since 2023 reflects sustained cost control and/or product-mix improvements that are translating into higher operating and net profitability. Improved margins enhance durable earnings power and buffer against input-cost shocks, supporting long-term cash generation and reinvestment capacity.
Read all positive factors
Lion (4912) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥487.84B
Dividend Yield1.61%
Average Volume (3M)1.11M
Price to Earnings (P/E)17.7
Beta (1Y)0.33
Revenue Growth6.21%
EPS Growth37.97%
CountryJP
Employees8,346
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)104.18
Shares Outstanding279,782,750
10 Day Avg. Volume1,063,460
30 Day Avg. Volume1,106,010
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)1.41
Price to Sales (P/S)1.08
P/FCF Ratio20.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,935.00Price Target Upside16.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)92.47
Revenue Forecast (FY)¥434.42B
Lion Business Overview & Revenue Model
Company Description
Headquartered in Tokyo, Japan, and established in 1891, Lion Corporation is a global manufacturer and distributor of an extensive range of consumer and industrial products. Its operations are organized into three primary divisions: Consumer Produc...
How the Company Makes Money
null...
Lion Earnings Call Summary
Earnings Call Date:Nov 07, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted an increase in net sales and profits, driven by effective price revisions and structural reforms. However, challenges such as impairment losses, a decline in domestic sales, and a slowdown in certain overseas markets were also noted. The partnership with Japan Activation Capital is a strategic move to bolster future growth.Positive Updates
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Negative Updates
Impairment Loss on Domestic Facilities
Impairment loss of approximately JPY 6.2 billion due to streamlining of domestic home care production facilities.
Read all updates
Q3-2024 Updates
Positive
Negative
Increased Net Sales and Profits
Net sales were JPY 301.1 billion, up 1.7% year-on-year. Core operating income was JPY 18.6 billion, an increase of JPY 6 billion year-on-year.
Read all positive updates
Company Guidance
In the earnings call for Q3 2024, Lion Corporation reported a 1.7% increase in net sales to JPY 301.1 billion, with a core operating income rise of JPY 6 billion year-on-year, reaching JPY 18.6 billion. The EBITDA was JPY 32.5 billion, up by JPY 6.4 billion, with a margin increase of 2 percentage points to 10.8%. Despite an impairment loss of JPY 6.2 billion due to domestic production facility streamlining, the company maintained its full-year forecast, attributing the resilient performance to price revisions and cost reductions, specifically mentioning a JPY 2.8 billion price revision impact and a total cost reduction of JPY 2.2 billion. The consumer product sales in Japan fell by 4.3%, whereas overseas sales showed sustained double-digit growth. The company plans further asset sales in Q4 to support ongoing structural reforms, aiming for a total shareholder return ratio of 91.9% with a dividend set at JPY 27 per share.Lion Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 439.47B | 422.09B | 412.94B | 402.77B | 389.87B | 366.23B |
| Gross Profit | 205.09B | 193.92B | 188.78B | 180.60B | 174.61B | 179.10B |
| EBITDA | 64.60B | 61.79B | 54.17B | 43.35B | 49.14B | 48.48B |
| Net Income | 28.82B | 27.59B | 21.20B | 14.63B | 21.94B | 23.76B |
Balance Sheet | ||||||
| Total Assets | 532.80B | 528.60B | 497.17B | 486.36B | 469.28B | 428.02B |
| Cash, Cash Equivalents and Short-Term Investments | 83.40B | 88.09B | 102.24B | 85.53B | 101.08B | 97.25B |
| Total Debt | 31.83B | 54.44B | 29.74B | 30.34B | 32.17B | 8.37B |
| Total Liabilities | 174.23B | 180.17B | 181.47B | 188.23B | 190.11B | 163.01B |
| Stockholders Equity | 332.76B | 322.73B | 293.72B | 280.32B | 264.25B | 251.57B |
Cash Flow | ||||||
| Free Cash Flow | 38.41B | 22.57B | 25.60B | 6.34B | 23.47B | -17.99B |
| Operating Cash Flow | 48.34B | 40.65B | 43.66B | 30.07B | 41.96B | 19.30B |
| Investing Cash Flow | -31.98B | -43.37B | -7.19B | -34.37B | -19.54B | -34.18B |
| Financing Cash Flow | -17.29B | -12.50B | -21.67B | -12.19B | -19.82B | -10.22B |
Lion Technical Analysis
Positive
1659.50
Price Trends
1673.41
Positive
1634.91
Positive
1634.40
Positive
Market Momentum
17.39
Negative
64.37
Neutral
57.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4912, the sentiment is Positive. The current price of 1659.5 is below the 20-day moving average (MA) of 1699.45, below the 50-day MA of 1673.41, and above the 200-day MA of 1634.40, indicating a bullish trend. The MACD of 17.39 indicates Negative momentum. The RSI at 64.37 is Neutral, neither overbought nor oversold. The STOCH value of 57.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4912.
Lion Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥1.87T | 27.53 | 7.73% | 2.09% | 0.29% | -22.26% | |
75 Outperform | ¥487.84B | 17.72 | 8.90% | 1.74% | 6.21% | 37.97% | |
74 Outperform | ¥3.31T | 24.59 | 12.16% | 2.36% | 6.19% | 21.69% | |
72 Outperform | ¥664.56B | 19.35 | 12.11% | 1.82% | 9.67% | -2.92% | |
68 Neutral | ¥337.74B | 24.46 | 3.71% | 2.42% | 3.22% | 357.77% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ¥405.89B | 249.66 | 1.46% | 1.92% | 3.71% | -86.23% |
* Consumer Defensive Sector Average
JP:4912
Lion
1,797.50
202.86
12.72%
JP:4452
Kao
3,654.00
292.85
8.71%
JP:4967
Kobayashi Pharmaceutical Co
5,473.00
145.19
2.73%
JP:4922
Kose
5,920.00
232.28
4.08%
JP:4527
Rohto Pharmaceutical Co
2,862.50
406.71
16.56%
JP:8113
Unicharm
1,023.00
35.17
3.56%
Lion Corporate Events
Lion lifts first-half earnings on oral care and overseas consolidation
Aug 7, 2026
Lion Corporation reported first-half 2026 results showing net sales of ¥216.83 billion, up 8.7% year on year, driven by strong oral healthcare sales in Japan and contributions from consolidated subsidiaries Merap Lion in Vietnam and PNB in Au...
Lion Posts Strong H1 2026 Profits but Sees Full-Year Earnings Dip
Aug 7, 2026
Lion Corporation reported strong results for the first half of 2026, with net sales rising 8.7% year on year to ¥216.8 billion and operating profit surging 54.7%, supported by a 21.3% increase in core operating income. Profit attributable to ...
Lion lifts Q1 profit on high value-added oral care push, keeps 2026 outlook
May 12, 2026
Lion Corporation reported that first-quarter 2026 net sales rose 5.3% year on year to ¥99.20 billion, with core operating income up 13.8% to ¥6.01 billion and an EBITDA margin of 11.1%, driven by a shift to higher value-added oral care p...
Lion Corporation Delivers Strong Q1 2026 Earnings and Confirms Full-Year Outlook
May 12, 2026
Lion Corporation reported solid first-quarter 2026 results, with net sales rising 5.3% year on year to ¥99.2 billion and operating profit climbing 11.6% to ¥6.3 billion, supported by a 13.8% increase in core operating income. Profit attr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.